cPacket Networks to Offer Cloud Visibility Service with Amazon Virtual Private Cloud Traffic Mirroring
New cCloud Solution Provides Customers Access to Network-Level Packet Data for Performance and Security Monitoring
SAN JOSE, Calif., June 25, 2019 (GLOBE NEWSWIRE) -- cPacket Networks, a leading provider of next-generation network performance/security monitoring and packet brokering solutions, has launched the cCloud cloud-based network visibility-as-a-service (VaaS) offering by working with Amazon Web Services (AWS) and leveraging the traffic mirroring feature offered by Amazon Virtual Private Cloud (Amazon VPC).
“While many of our customers are migrating workloads to the cloud, until now it happened to be a black-box for them, from a performance and security perspective. The cPacket solution builds on Amazon Virtual Private Cloud (Amazon VPC) traffic mirroring to remove blind spots, provide complete visibility, and make the cloud transition smooth for our customers,” said Brendan O’Flaherty, CEO of cPacket Networks.
Without the rich insights of packet data, full visibility is compromised as today’s log-based tools have several limitations. The traffic mirroring service is a new feature available as part of Amazon VPC, designed to more easily provide deep network traffic visibility. Traffic mirroring duplicates the traffic from Amazon Elastic Compute Cloud (Amazon EC2) instances within an Amazon VPC and forwards it to performance and security monitoring tools. Because traffic mirroring is built in Amazon VPC, it removes the need for AWS customers to deploy an ad-hoc forwarding agent in each of their Amazon VPCs for every monitoring tool they have. cPacket cCloud allows deep inspection, threat investigation, performance, and capacity planning.
“cPacket’s cCloud solution for Amazon VPC comprises of cClear-V, cVu-V, and cStor-V series cloud-native instances which provide a complete visibility service chain including virtual packet brokering, packet data capture, analysis and storage, and single pane of glass analytics across the hybrid environment,” said Ron Nevo, CTO of cPacket Networks.
With cPacket’s new cCloud offering, customers can natively replicate and monitor network traffic to their tools within their Amazon VPC, and further cut the complexity and cost of using forwarding agents or container-based sensors. The result is simplicity, elasticity, and cost savings.
The new solution is now available for demonstration and will be available on AWS marketplace in near future. To learn more, visit www.cpacket.com .
About cPacket Networks
cPacket Networks enables organizations around the world to keep their business running. Leading enterprises, service providers, and governments rely on cPacket solutions for improved agility, higher performance, and greater efficiency.
cPacket delivers visibility you can trust through network monitoring and packet brokering solutions to solve today’s biggest network challenges. Our cutting-edge technology enables network and security teams to proactively identify issues in real-time before negatively impacting end-users. Only cPacket inspects all the packets delivering the right data to the right tools at the right time and provides detailed network analytics dashboards. Our solutions are designed to overcome scalability issues and reduce troubleshooting time. The result: increased security, reduced complexity, lower costs, and a faster ROI.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Scanship Holding ASA : Invitation to 3Q2019 Trading update on Tuesday 22 October14.10.2019 21:52:00 CEST | Press release
Welcome to Scanship Holding ASA's 3Q2019 Trading update at hrs. 12.00 on Tuesday 22 October in Oslo. With the recent acquisition of ETIA, Scanship has significantly broadened and expanded its adressable market, and the presentation will include more insight to forward growth strategies within the various landbased markets. Special attention will be given on Scanship's value proposition for the European biogas market and within chemical recycling of plastic waste. The presentation will be held at MESH in Tordenskioldsgate 3, and a light lunch will be served. Please notify Scanship by e-mail to attend: firstname.lastname@example.org, or cell + 47 928 88 728 Venue: MESH, the Lounge, Tordenskiolds gate 3, 0160 Oslo For further queries, please contact: Henrik Badin - CEO Scanship Holding ASA Tel: +47 90 78 98 25 Email: email@example.com ABOUT SCANSHIP HOLDING ASA Scanship delivers world leading solutions for cleaner oceans in the Cruise and Aquaculture industries. Scanship provides advan
Notice of extraordinary general meeting in Oasmia Pharmaceutical AB14.10.2019 20:48:00 CEST | Press release
The shareholders of Oasmia Pharmaceutical AB (the “Company”) are hereby given notice of the extraordinary general meeting on Wednesday 6 November 2019, at 14:00 CET, at the offices of the Company, Vallongatan 1, 752 28 Uppsala. The registration opens at 13:30 CET. NOTICE OF ATTENDANCE Shareholders who wish to participate in the general meeting must be recorded in the share register kept by Euroclear Sweden AB as of Wednesday 30 October 2019 and give notice of intent to participate to the Company no later than on Wednesday 30 October 2019, either by letter to Oasmia Pharmaceutical AB, Vallongatan 1, 752 28 Uppsala, Sweden, by facsimile: +46 (0)18-51 08 73 or by e-mail: firstname.lastname@example.org, and specify the number of advisors (maximum two). If shareholder’s attendance and right at the meeting will be exercised by proxy, we would be grateful if such is provided in connection with the notification of attendance. A proxy form is available to shareholders upon request and is avaliable at the Comp
Kallelse till extra bolagsstämma i Oasmia Pharmaceutical AB14.10.2019 20:48:00 CEST | Pressemelding
Aktieägarna i Oasmia Pharmaceutical AB (”Bolaget”) kallas härmed till extra bolagsstämma onsdagen den 6 november 2019 kl. 14:00, i Bolagets lokaler, Vallongatan 1, 752 28 Uppsala. Inregistrering påbörjas kl. 13:30. ANMÄLAN Aktieägare som önskar delta vid bolagsstämman skall dels vara införd i den av Euroclear Sweden AB förda aktieboken onsdagen den 30 oktober 2019, dels anmäla sitt deltagande till Bolaget senast onsdagen den 30 oktober 2019 under adress Oasmia Pharmaceutical AB, Vallongatan 1, 752 28 Uppsala, per fax: 018-51 08 73 eller via e-post: email@example.com, varvid antalet biträden skall anges (högst två). Om deltagande skall ske med stöd av fullmakt är vi tacksamma om sådan ges in redan i samband med anmälan. Fullmakten får inte vara äldre än ett år gammal, dock att fullmakten får vara äldre än ett år om det framgår att den är giltig för en längre period, längst fem år. Fullmaktsformulär tillhandahålls aktieägare på begäran och finns tillgängligt hos Bolaget och på Bolagets we
The Board of Directors in Oasmia proposes a rights issue of approximately SEK 400 million14.10.2019 20:46:00 CEST | Press release
The Board of Directors in Oasmia Pharmaceutical AB (”Oasmia” or the ”Company”) today announces a notice to an extra general meeting on 6 November 2019. It is proposed that the extra general meeting resolves to authorise the Board of Directors to carry out a rights issue of approximately SEK 400 million (the “Rights Issue”). The proceeds from the Rights Issue will primarily be used to finance and accelerate the commercialization of Apealea® and capture new business opportunities based on the Company's proprietary XR17 platform. Moreover, Oasmia intends to create a stable financial position enabling a solid platform for growth. The Company’s major shareholder Per Arwidsson through Arwidsro Investment AB and related parties (“Arwidsro”) has undertaken to subscribe for its pro-rata share in the Rights Issue, corresponding to approximately SEK 100 million or 25 percent. Oasmia has also received a financing commitment from Arwidsro enabling Oasmia to repay the convertible loan on 31 October
Styrelsen i Oasmia föreslår en företrädesemission om cirka 400 MSEK14.10.2019 20:46:00 CEST | Pressemelding
Styrelsen i Oasmia Pharmaceutical AB (”Oasmia” eller ”Bolaget”) offentliggör idag kallelse till extra bolagsstämma den 6 november 2019. Bolagsstämman föreslås besluta att bemyndiga styrelsen att genomföra en företrädesemission om cirka 400 MSEK (”Företrädesemissionen”). Likviden från Företrädesemissionen ska huvudsakligen användas för att finansiera och accelerera kommersialiseringen av Apealea® samt tillvarata nya affärsmöjligheter baserade på Bolagets egenutvecklade XR17-plattform. Därutöver avser Oasmia att skapa en stabil finansiell position för att möjliggöra framtida tillväxt. Bolagets största aktieägare Per Arwidsson via Arwidsro Investment AB och närstående (”Arwidsro”) har åtagit sig att teckna sig för sin pro rata-andel i Företrädesemissionen, motsvarande cirka 100 MSEK eller 25 procent. Oasmia har också fått ett finansieringsåtagande från Arwidsro som möjliggör för Oasmia att återbetala det utestående konvertibellånet den 31 oktober 2019. Sammanfattning Styrelsen offentliggö
Arion Bank: Discontinued operations and assets held for sale have negative impact on Q3 2019 financial results14.10.2019 20:29:00 CEST | Press release
Discontinued operations and assets held for sale will have a negative impact of approximately ISK 3 billion after tax on Arion Bank’s Q3 2019 financial results, compared with a loss of ISK 715 million in Q2 2019. Discontinued operations held for sale refer to assets or companies which the Bank intends to sell in the next few months and are placed below net earnings from continuing operations in the income statement. Increased losses in the quarter are attributable to three factors: As a result of the challenging markets, including the low global price of silicon, Arion Bank is making an impairment of ISK 1.5 billion in respect of assets owned by Stakksberg. Stakksberg is a holding company for the silicon plant at Helguvík which is in the process of being sold. Preparations to sell the plant have been ongoing and an environmental impact assessment has been commissioned and new agreements with energy companies negotiated. Due to difficult conditions in the travel industry, Arion Bank is